BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35821619)

  • 21. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 22. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.
    Lin-Tsai O; Clark PE; Miller NL; Fowke JH; Hameed O; Hayward SW; Strand DW
    Prostate; 2014 May; 74(6):669-79. PubMed ID: 24500928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NF-κB and androgen receptor variant expression correlate with human BPH progression.
    Austin DC; Strand DW; Love HL; Franco OE; Jang A; Grabowska MM; Miller NL; Hameed O; Clark PE; Fowke JH; Matusik RJ; Jin RJ; Hayward SW
    Prostate; 2016 Apr; 76(5):491-511. PubMed ID: 26709083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
    Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
    J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
    Madersbacher S; Sampson N; Culig Z
    Gerontology; 2019; 65(5):458-464. PubMed ID: 30943489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase.
    Tao R; Liu E; Zhao X; Han L; Yu B; Mao H; Yang W; Gao X
    Phytomedicine; 2022 Jul; 102():154169. PubMed ID: 35636178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracts of
    Song KH; Seo CS; Yang WK; Gu HO; Kim KJ; Kim SH
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33803357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
    Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
    Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
    Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy.
    Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    Arch Ital Urol Androl; 2022 Dec; 94(4):521-524. PubMed ID: 36576460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
    Jin BR; An HJ
    Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia.
    Liu Z; Lin Z; Cao F; Jiang M; Jin S; Cui Y; Niu YN
    BMC Urol; 2022 Nov; 22(1):172. PubMed ID: 36344974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.